ANGELYC (Analysis of Genomes to Eliminate Lymphoid Cancer) Project

With plans to analyze the genomes of all types of lymphoid cancers, this project intends to identify a number of possible cancer biomarkers. Each biomarker is a signal or target at which researchers can aim new therapeutics. A deeper understanding of cancer and how to treat it represents a movement away from cancer as a terminal disease and towards it being a chronic one. Such new therapeutics hold the promise for greater treatment efficacy and fewer side effects. These new options hold promise for the up to 50 per cent of lymphoid cancer patients who cannot be treated with standard therapy.